author-photo

Steven Jungerwirth

8

Papers

426

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

THU0195 Preferential Inhibition of IL-6 Relative To IL-7 Signaling Pathways by ABT-494: Exposure-Response Analysis of ex-Vivo Data from Two Phase 1 Clinical Trials and Comparison To Tofacitinib

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (9)
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

2016 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (76)
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy.

2016 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (70)
OP0223 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis with An Inadequate Response To Methotrexate

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)